Edition:
United Kingdom

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

52.97USD
7:42pm BST
Change (% chg)

$-0.96 (-1.78%)
Prev Close
$53.93
Open
$53.26
Day's High
$53.56
Day's Low
$52.51
Volume
84,756
Avg. Vol
165,507
52-wk High
$57.99
52-wk Low
$31.98

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals Says Had About $528 Mln Of Cash, Cash Equivalents And Investments As Of Dec 31
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS INC - AS OF DECEMBER 31, 2018, HAD ABOUT $528 MILLION OF CASH, CASH EQUIVALENTS, AND INVESTMENTS.  Full Article

Arena Pharmaceuticals Reports Positive Long-Term Data From The Open-Label Extension Of The Phase 2 Oasis Trial
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS REPORTS POSITIVE LONG-TERM DATA FROM THE OPEN-LABEL EXTENSION OF THE PHASE 2 OASIS TRIAL EVALUATING ETRASIMOD FOR TREATMENT OF ULCERATIVE COLITIS.ARENA PHARMACEUTICALS INC - ETRASIMOD DEMONSTRATED CLINICAL RESPONSE AND DURABLE, LONG-TERM CLINICAL REMISSION.ARENA PHARMACEUTICALS INC - ETRASIMOD DEMONSTRATED FAVORABLE LONG-TERM SAFETY AND TOLERABILITY.  Full Article

Arena Pharma Reports Positive Phase 2A Results For Olorinab
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS REPORTS POSITIVE PHASE 2A RESULTS FOR OLORINAB IN PATIENTS WITH ABDOMINAL PAIN ASSOCIATED WITH CROHN'S DISEASE.ARENA PHARMACEUTICALS INC - OLORINAB APPEARED SAFE AND GENERALLY WELL TOLERATED.ARENA PHARMACEUTICALS INC - ARENA INTENDS TO PROGRESS OLORINAB CLINICAL PROGRAM TARGETING GASTROINTESTINAL PAIN.ARENA PHARMACEUTICALS INC - OLORINAB DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT IN ABDOMINAL PAIN OVER 8 WEEKS OF TREATMENT.ARENA PHARMACEUTICALS INC - TREATMENT EFFECTS WERE DEMONSTRATED EARLY AND WERE CONSISTENT OVER 8-WEEK TREATMENT PERIOD.ARENA PHARMACEUTICALS INC - ALL PATIENTS WITH EVALUABLE DATA AT WEEK 8 EXHIBITED A PRE-DEFINED CLINICAL RESPONSE OF ≥30% CHANGE FROM BASELINE IN AAPS.  Full Article

Arena Pharmaceuticals Reports Q2 Loss Per Share Of $0.65
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $4.0 MILLION.Q2 LOSS PER SHARE $0.65.Q2 REVENUE VIEW $2.9 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.64 -- THOMSON REUTERS I/B/E/S.  Full Article

Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80
Tuesday, 8 May 2018 

May 8 (Reuters) - Arena Pharmaceuticals Inc ::EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018.ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $1.8 MILLION.Q1 LOSS PER SHARE $0.80.Q1 REVENUE VIEW $2.8 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.68 -- THOMSON REUTERS I/B/E/S.  Full Article

Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ARENA PHARMACEUTICALS INC - TO OFFER 7.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA.ARENA PHARMACEUTICALS INC - C-BRIDGE CAPITAL HAS INVESTED $50 MILLION TO FUND EVEREST MEDICINES LIMITED.ARENA PHARMACEUTICALS - AS PER AGREEMENT, CO WILL RECEIVE AN UPFRONT PAYMENT OF $12 MILLION.ARENA PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ARENA IS ELIGIBLE TO RECEIVE UP TO $212 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS.  Full Article

Arena Pharmaceuticals reports Q3 loss per share $0.86
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Arena Pharmaceuticals Inc ::Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.86.Q3 revenue $7.9 million.Q3 revenue view $5.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals Inc - ‍expect to complete full enrollment for etrasimod phase 2 study in ulcerative colitis this week​.Arena Pharmaceuticals Inc - ‍initiated etrasimod phase 2 study in primary biliary cholangitis​.  Full Article